Details for New Drug Application (NDA): 203774
✉ Email this page to a colleague
NDA 203774 describes PEMETREXED DISODIUM, which is a drug marketed by Accord Hlthcare, Amneal, Apotex, Baxter Hlthcare Corp, Biocon Pharma, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hetero Labs Ltd Vi, Hospira, Jiangsu Hansoh Pharm, Meitheal, Nang Kuang Pharm Co, Norvium Bioscience, Prinston Inc, Qilu Pharm Hainan, Reliance Life, Zydus Pharms, and Sandoz, and is included in twenty-three NDAs. It is available from twenty suppliers. Additional details are available on the PEMETREXED DISODIUM profile page.
The generic ingredient in PEMETREXED DISODIUM is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
The generic ingredient in PEMETREXED DISODIUM is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
Summary for 203774
| Tradename: | PEMETREXED DISODIUM |
| Applicant: | Apotex |
| Ingredient: | pemetrexed disodium |
| Patents: | 0 |
Pharmacology for NDA: 203774
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
Medical Subject Heading (MeSH) Categories for 203774
Suppliers and Packaging for NDA: 203774
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 203774 | ANDA | Apotex Corp | 60505-6065 | 60505-6065-0 | 1 VIAL in 1 CARTON (60505-6065-0) / 4 mL in 1 VIAL |
| PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 203774 | ANDA | BluePoint Laboratories | 68001-543 | 68001-543-41 | 1 VIAL in 1 CARTON (68001-543-41) / 4 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 100MG BASE/VIAL | ||||
| Approval Date: | May 25, 2022 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | May 25, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
